Clinical Trial Update: Safety and Immunogenicity of 2 Formulations of Tuberculosis Vaccine GSK692342 Given at 0,1 Months to Healthy Adults [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety and immunogenicity of two formulations of the TB vaccine GSK692342 in healthy adults.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• GSK692342 (GSK692342)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Tuberculosis | Phase 2 | Status: COMPLETED | Results posted: 2018-08-13